AG˹ٷ

STOCK TITAN

[Form 4] VolitionRX Limited Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 discloses that Salvatore T. Butera, CEO of Volition Veterinary and an officer of VolitionRx (VNRX), had 6,393 common shares automatically withheld on 01-Aug-2025 (code “F�) to cover taxes due on the vesting of 23,377 restricted stock units received in lieu of cash compensation. The withheld shares were cancelled by the company; neither the insider nor VolitionRx executed an open-market sale. After the transaction Mr. Butera owns 303,524 shares directly and 99,350 shares jointly with his spouse, keeping his overall economic stake largely intact. No derivative securities were transacted. Because the action was tax-related and not a discretionary sale or purchase, it carries limited insight into management’s view of valuation, but it does confirm the continued equity alignment of a key executive.

Il Modulo 4 rivela che Salvatore T. Butera, CEO di Volition Veterinary e dirigente di VolitionRx (VNRX), ha avuto 6.393 azioni ordinarie trattenute automaticamente il 01-ago-2025 (codice “F�) per coprire le tasse dovute sulla maturazione di 23.377 unità di azioni vincolate ricevute in sostituzione della retribuzione in contanti. Le azioni trattenute sono state cancellate dalla società; né l’insider né VolitionRx hanno effettuato una vendita sul mercato aperto. Dopo la transazione, il signor Butera possiede 303.524 azioni direttamente e 99.350 azioni congiuntamente con il coniuge, mantenendo sostanzialmente intatta la sua partecipazione economica complessiva. Non sono stati effettuati scambi di titoli derivati. Poiché l’operazione è stata legata a questioni fiscali e non a una vendita o acquisto discrezionale, fornisce informazioni limitate sulla valutazione da parte della direzione, ma conferma il continuo allineamento azionario di un dirigente chiave.

El Formulario 4 revela que Salvatore T. Butera, CEO de Volition Veterinary y funcionario de VolitionRx (VNRX), tuvo 6,393 acciones ordinarias retenidas automáticamente el 01-ago-2025 (código “F�) para cubrir impuestos adeudados por la consolidación de 23,377 unidades restringidas de acciones recibidas en lugar de compensación en efectivo. Las acciones retenidas fueron canceladas por la compañía; ni el insider ni VolitionRx realizaron una venta en el mercado abierto. Tras la transacción, el Sr. Butera posee 303,524 acciones directamente y 99,350 acciones conjuntamente con su cónyuge, manteniendo su participación económica general prácticamente intacta. No se negociaron valores derivados. Dado que la acción fue por motivos fiscales y no una venta o compra discrecional, ofrece una visión limitada sobre la valoración por parte de la dirección, pero confirma la continua alineación accionarial de un ejecutivo clave.

Form 4� 따르�, Volition Veterinary� CEO이자 VolitionRx(VNRX)� 임원� Salvatore T. Butera� 2025� 8� 1일에 23,377개의 제한 주식 단위가 현금 보상 대� 지급됨� 따라 발생� 세금 납부� 위해 6,393개의 보통주가 자동으로 원천징수되었습니�(코드 “F�). 원천징수� 주식은 회사� 의해 취소되었으며, 내부자나 VolitionRx 모두 공개 시장에서 매도하지 않았습니�. 거래 이후 Butera 씨는 직접 303,524�배우자왶� 공동으로 99,350�� 보유하여 전체 경제� 지분을 거의 유지하고 있습니다. 파생 증권 거래� 없었습니�. � 조치� 세금 관련으� 임의 매매가 아니� 때문� 경영진의 평가 견해� 대� 통찰력은 제한적이지�, 핵심 임원� 지속적� 주식 정렬� 확인� 줍니�.

Le formulaire 4 révèle que Salvatore T. Butera, PDG de Volition Veterinary et dirigeant de VolitionRx (VNRX), a vu 6 393 actions ordinaires automatiquement retenues le 01-août-2025 (code « F ») pour couvrir les impôts dus lors de l'acquisition de 23 377 unités d'actions restreintes reçues en lieu et place d'une rémunération en espèces. Les actions retenues ont été annulées par la société ; ni l'initié ni VolitionRx n'ont effectué de vente sur le marché ouvert. Après la transaction, M. Butera détient 303 524 actions en propre et 99 350 actions conjointement avec son conjoint, conservant ainsi sa participation économique globale quasiment intacte. Aucun titre dérivé n'a été négocié. Comme il s'agissait d'une opération liée à la fiscalité et non d'une vente ou d'un achat discrétionnaire, cela apporte peu d'informations sur la perception de la valorisation par la direction, mais confirme l'alignement continu des intérêts en actions d'un cadre clé.

Formular 4 offenbart, dass Salvatore T. Butera, CEO von Volition Veterinary und Funktionär von VolitionRx (VNRX), am 01.08.2025 6.393 Stammaktien automatisch einbehalten wurden (Code „F�), um Steuern auf die Vesting von 23.377 Restricted Stock Units zu begleichen, die anstelle einer Barvergütung erhalten wurden. Die einbehaltenen Aktien wurden vom Unternehmen storniert; weder der Insider noch VolitionRx führten einen Verkauf am offenen Markt durch. Nach der Transaktion besitzt Herr Butera 303.524 Aktien direkt und 99.350 Aktien gemeinsam mit seinem Ehepartner, wodurch sein gesamtes wirtschaftliches Interesse weitgehend erhalten bleibt. Es wurden keine Derivate gehandelt. Da die Maßnahme steuerbedingt war und kein diskretionärer Verkauf oder Kauf, gibt sie nur begrenzte Einblicke in die Bewertung durch das Management, bestätigt jedoch die fortgesetzte Aktienausrichtung eines wichtigen Managers.

Positive
  • No open-market sale; shares were cancelled for taxes, avoiding potential selling pressure.
Negative
  • Slight reduction in insider ownership (-6,393 shares) as a result of withholding, though economically immaterial.

Insights

TL;DR: Routine tax withholding; insider still holds ~403k shares, no open-market activity—neutral signal.

The Form 4 shows a non-discretionary share cancellation to satisfy tax obligations tied to RSU vesting. Such “F� code events are mechanically triggered and do not indicate sentiment. Post-event ownership remains substantial, preserving alignment with shareholders. The lack of derivative activity or open-market sales suggests no adverse liquidity concerns, but likewise offers no bullish signal. Given the small share count relative to VolitionRx’s 60 m+ outstanding shares, market impact is negligible.

Il Modulo 4 rivela che Salvatore T. Butera, CEO di Volition Veterinary e dirigente di VolitionRx (VNRX), ha avuto 6.393 azioni ordinarie trattenute automaticamente il 01-ago-2025 (codice “F�) per coprire le tasse dovute sulla maturazione di 23.377 unità di azioni vincolate ricevute in sostituzione della retribuzione in contanti. Le azioni trattenute sono state cancellate dalla società; né l’insider né VolitionRx hanno effettuato una vendita sul mercato aperto. Dopo la transazione, il signor Butera possiede 303.524 azioni direttamente e 99.350 azioni congiuntamente con il coniuge, mantenendo sostanzialmente intatta la sua partecipazione economica complessiva. Non sono stati effettuati scambi di titoli derivati. Poiché l’operazione è stata legata a questioni fiscali e non a una vendita o acquisto discrezionale, fornisce informazioni limitate sulla valutazione da parte della direzione, ma conferma il continuo allineamento azionario di un dirigente chiave.

El Formulario 4 revela que Salvatore T. Butera, CEO de Volition Veterinary y funcionario de VolitionRx (VNRX), tuvo 6,393 acciones ordinarias retenidas automáticamente el 01-ago-2025 (código “F�) para cubrir impuestos adeudados por la consolidación de 23,377 unidades restringidas de acciones recibidas en lugar de compensación en efectivo. Las acciones retenidas fueron canceladas por la compañía; ni el insider ni VolitionRx realizaron una venta en el mercado abierto. Tras la transacción, el Sr. Butera posee 303,524 acciones directamente y 99,350 acciones conjuntamente con su cónyuge, manteniendo su participación económica general prácticamente intacta. No se negociaron valores derivados. Dado que la acción fue por motivos fiscales y no una venta o compra discrecional, ofrece una visión limitada sobre la valoración por parte de la dirección, pero confirma la continua alineación accionarial de un ejecutivo clave.

Form 4� 따르�, Volition Veterinary� CEO이자 VolitionRx(VNRX)� 임원� Salvatore T. Butera� 2025� 8� 1일에 23,377개의 제한 주식 단위가 현금 보상 대� 지급됨� 따라 발생� 세금 납부� 위해 6,393개의 보통주가 자동으로 원천징수되었습니�(코드 “F�). 원천징수� 주식은 회사� 의해 취소되었으며, 내부자나 VolitionRx 모두 공개 시장에서 매도하지 않았습니�. 거래 이후 Butera 씨는 직접 303,524�배우자왶� 공동으로 99,350�� 보유하여 전체 경제� 지분을 거의 유지하고 있습니다. 파생 증권 거래� 없었습니�. � 조치� 세금 관련으� 임의 매매가 아니� 때문� 경영진의 평가 견해� 대� 통찰력은 제한적이지�, 핵심 임원� 지속적� 주식 정렬� 확인� 줍니�.

Le formulaire 4 révèle que Salvatore T. Butera, PDG de Volition Veterinary et dirigeant de VolitionRx (VNRX), a vu 6 393 actions ordinaires automatiquement retenues le 01-août-2025 (code « F ») pour couvrir les impôts dus lors de l'acquisition de 23 377 unités d'actions restreintes reçues en lieu et place d'une rémunération en espèces. Les actions retenues ont été annulées par la société ; ni l'initié ni VolitionRx n'ont effectué de vente sur le marché ouvert. Après la transaction, M. Butera détient 303 524 actions en propre et 99 350 actions conjointement avec son conjoint, conservant ainsi sa participation économique globale quasiment intacte. Aucun titre dérivé n'a été négocié. Comme il s'agissait d'une opération liée à la fiscalité et non d'une vente ou d'un achat discrétionnaire, cela apporte peu d'informations sur la perception de la valorisation par la direction, mais confirme l'alignement continu des intérêts en actions d'un cadre clé.

Formular 4 offenbart, dass Salvatore T. Butera, CEO von Volition Veterinary und Funktionär von VolitionRx (VNRX), am 01.08.2025 6.393 Stammaktien automatisch einbehalten wurden (Code „F�), um Steuern auf die Vesting von 23.377 Restricted Stock Units zu begleichen, die anstelle einer Barvergütung erhalten wurden. Die einbehaltenen Aktien wurden vom Unternehmen storniert; weder der Insider noch VolitionRx führten einen Verkauf am offenen Markt durch. Nach der Transaktion besitzt Herr Butera 303.524 Aktien direkt und 99.350 Aktien gemeinsam mit seinem Ehepartner, wodurch sein gesamtes wirtschaftliches Interesse weitgehend erhalten bleibt. Es wurden keine Derivate gehandelt. Da die Maßnahme steuerbedingt war und kein diskretionärer Verkauf oder Kauf, gibt sie nur begrenzte Einblicke in die Bewertung durch das Management, bestätigt jedoch die fortgesetzte Aktienausrichtung eines wichtigen Managers.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Butera Salvatore Thomas

(Last) (First) (Middle)
1489 WEST WARM SPRINGS ROAD
SUITE 110

(Street)
HENDERSON NV 89014

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VOLITIONRX LTD [ VNRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CEO - Volition Veterinary
3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/01/2025 F 6,393(1) D $0.64 303,524 D
Common Stock 99,350 D(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 23,377 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.
2. These shares of common stock are jointly owned by the reporting person and his spouse.
Remarks:
/s/ Salvatore Thomas Butera 08/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did VNRX insider Salvatore Butera report on Form 4?

He reported 6,393 shares withheld and cancelled on 01-Aug-2025 to pay taxes on 23,377 vested RSUs.

Did the VNRX officer sell shares on the open market?

No. The transaction was coded "F", indicating shares were withheld for tax and not publicly sold.

How many VNRX shares does Salvatore Butera own after the transaction?

He holds 303,524 shares directly plus 99,350 jointly with his spouse.

Were any options or other derivatives exercised?

No derivative securities were acquired or disposed of in this filing.

Is this Form 4 filing impactful for VNRX investors?

Impact is minimal; the transaction is routine tax withholding and doesn’t reflect insider sentiment.
Volitionrx

NYSE:VNRX

VNRX Rankings

VNRX Latest News

VNRX Latest SEC Filings

VNRX Stock Data

66.55M
83.43M
18.4%
20.49%
0.35%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
United States
HENDERSON